The Centre for Experimental Cancer Medicine (CECM) at Barts Cancer Institute was created in 2008.
- Provides design and management support for over 200 trials including national, pharmaceutical and investigator led studies
- Centralises all staff involved in clinical trials within the Institute to ensure compliance with the European Directive on Good Clinical Practice.
More information about our local & national clinical trials and work with St. Bartholomew's Hospital:
If you are a patient interested in cancer clinical trials, please visit this link for further information on clinical trials running at St. Bartholomew’s Hospital. You are also advised to speak to your treating clinician.
If you are a clinician, please contact the email address on the portfolio spreadsheet for further information about specific trials being managed by the Centre for Experimental Cancer Medicine.
For information on our portfolio of hosted studies (i.e.: sponsored by organisations other than Barts and The London NHS Trust or Queen Mary University of London) please contact firstname.lastname@example.org.
The Queen Mary Trials Advisory Group
In November 2009 the Centre for Experimental Cancer Medicine, in conjunction with the Cancer Prevention Trials Unit, set up a patient and public advisory group.
It is essential for our clinical trials units to be able to gauge public opinion regarding both the information being provided to participants of clinical trials, and also on the principles and priorities that have inspired the proposed studies.
The Queen Mary Trials Advisory Group (QMTAG) will assist the units by:
- Providing feedback on trial design/research proposals
- Reading and critiquing the patient documentation eg. Patient Information leaflet, Consent Forms.
- Evaluating consent procedures
- Representing the wider patient community by participating in meetings and discussion groups.
- Advising on how specific communities should be approached, and the need for trial-specific consumer groups